Details for Patent: 9,388,134
✉ Email this page to a colleague
Which drugs does patent 9,388,134 protect, and when does it expire?
Patent 9,388,134 protects ENTRESTO and is included in one NDA.
Protection for ENTRESTO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has seventy-one patent family members in thirty-five countries.
Summary for Patent: 9,388,134
Title: | Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Abstract: | A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi. |
Inventor(s): | Feng; Lili (Pine Brook, NJ), Godtfredsen; Sven Erik (Chatham, NJ), Sutton; Paul Allen (Parsippany, NJ), Prashad; Mahavir (Montville, NJ), Girgis; Michael J. (Montville, NJ), Hu; Bin (Green Brook, NJ), Liu; Yugang (Bridgewater, NJ), Blacklock; Thomas J. (East Hanover, NJ), Karpinski; Piotr Henryk (Lincoln Park, NJ) |
Assignee: | NOVARTIS, AG (Basel, CH) |
Application Number: | 14/311,788 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,388,134 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,388,134
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-001 | Jul 7, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-002 | Jul 7, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Novartis Pharms Corp | ENTRESTO | sacubitril; valsartan | TABLET;ORAL | 207620-003 | Jul 7, 2015 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,388,134
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 057882 | ⤷ Try a Trial | |||
Argentina | 106613 | ⤷ Try a Trial | |||
Argentina | 106614 | ⤷ Try a Trial | |||
Australia | 2006311481 | ⤷ Try a Trial | |||
Brazil | 122013025375 | ⤷ Try a Trial | |||
Brazil | PI0605921 | ⤷ Try a Trial | |||
Canada | 2590511 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |